Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNASDAQ:BHSTNASDAQ:ERASNASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$4.78+0.8%$6.12$4.60▼$11.16$368.13M0.872.91 million shs2.83 million shsBHSTBioHarvest Sciences$6.15-5.2%$5.69$6.15▼$7.38$101.01M2.277,947 shs4,487 shsERASErasca$1.26+4.6%$1.55$1.04▼$3.45$356.92M1.221.77 million shs3.04 million shsZVRAZevra Therapeutics$7.66+4.6%$7.86$4.20▼$9.76$414.53M1.98587,650 shs577,002 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+0.84%-14.49%-20.20%-32.77%-48.90%BHSTBioHarvest Sciences-5.24%-8.89%+22.27%+0.49%+614,999,900.00%ERASErasca+4.56%-14.86%-1.56%-53.33%-41.40%ZVRAZevra Therapeutics+4.64%-2.42%+4.50%-12.56%+49.76%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune1.9322 of 5 stars3.41.00.00.00.63.30.6BHSTBioHarvest SciencesN/AN/AN/AN/AN/AN/AN/AN/AERASErasca3.7706 of 5 stars4.51.00.00.03.23.31.3ZVRAZevra Therapeutics2.8067 of 5 stars4.61.00.00.02.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.89Moderate Buy$20.83335.84% UpsideBHSTBioHarvest Sciences 3.00Buy$13.00111.38% UpsideERASErasca 3.00Buy$4.83283.60% UpsideZVRAZevra Therapeutics 3.11Buy$22.29190.94% UpsideCurrent Analyst Ratings BreakdownLatest BHST, ERAS, ZVRA, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025ERASErascaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.003/21/2025ERASErascaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $3.003/21/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/18/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/14/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/13/2025ZVRAZevra TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $25.003/13/2025ZVRAZevra TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/13/2025ZVRAZevra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/12/2025ZVRAZevra TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$18.003/12/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/12/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K18,406.35N/AN/A$2.75 per share1.74BHSTBioHarvest Sciences$22.43M4.50N/AN/A($1.08) per share-5.69ERASErascaN/AN/AN/AN/A$2.10 per shareN/AZVRAZevra Therapeutics$23.61M17.56N/AN/A$1.71 per share4.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.34N/AN/AN/A-199,076.92%-55.81%-50.60%5/8/2025 (Estimated)BHSTBioHarvest Sciences-$12.56M-$1.25N/AN/AN/A-76.65%N/A-85.16%5/29/2025 (Estimated)ERASErasca-$125.04M-$0.74N/AN/AN/AN/A-42.26%-34.97%5/14/2025 (Estimated)ZVRAZevra Therapeutics-$46.05M-$2.24N/A38.30N/A-342.63%-159.54%-51.50%5/5/2025 (Estimated)Latest BHST, ERAS, ZVRA, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/31/2025Q4 2024BHSTBioHarvest Sciences-$0.12-$0.17-$0.05-$0.17$7.24 million$7.17 million3/20/2025Q4 2024ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A3/11/2025Q4 2024ZVRAZevra Therapeutics-$0.39-$0.67-$0.28-$0.67$8.93 million$12.00 million2/27/2025Q4 2024ALTAltimmune-$0.34-$0.33+$0.01-$0.33$0.00 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ABHSTBioHarvest SciencesN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A16.8716.87BHSTBioHarvest SciencesN/A0.800.48ERASErascaN/A11.0011.00ZVRAZevra Therapeutics0.842.882.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%BHSTBioHarvest SciencesN/AERASErasca67.78%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%BHSTBioHarvest SciencesN/AERASErasca21.50%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5077.01 million68.21 millionOptionableBHSTBioHarvest SciencesN/A16.43 millionN/AN/AERASErasca120283.27 million221.94 millionOptionableZVRAZevra Therapeutics2054.12 million52.10 millionOptionableBHST, ERAS, ZVRA, and ALT HeadlinesRecent News About These CompaniesZevra Therapeutics Files Preliminary ProxyMarch 31 at 4:12 PM | globenewswire.comAIGH Capital Management LLC Invests $6.58 Million in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)March 31 at 6:58 AM | marketbeat.comZevra Therapeutics management to meet with Cantor FitzgeraldMarch 26, 2025 | markets.businessinsider.comBank of New York Mellon Corp Sells 37,365 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)March 26, 2025 | marketbeat.comZevra Therapeutics (ZVRA) Projected to Post Earnings on ThursdayMarch 25, 2025 | americanbankingnews.comZevra Therapeutics Independent Director Acquires 33% More StockMarch 23, 2025 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Director John B. Bode Acquires 10,000 SharesMarch 22, 2025 | marketbeat.comInsider Buying: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Buys 10,000 Shares of StockMarch 22, 2025 | insidertrades.comZevra Therapeutics (ZVRA) to Release Quarterly Earnings on ThursdayMarch 20, 2025 | marketbeat.comHC Wainwright Predicts Lower Earnings for Zevra TherapeuticsMarch 17, 2025 | marketbeat.comCantor Fitzgerald Has Weak Forecast for ZVRA FY2025 EarningsMarch 15, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for ZVRA Q1 Earnings?March 15, 2025 | marketbeat.comEquities Analysts Offer Predictions for ZVRA Q1 EarningsMarch 15, 2025 | marketbeat.comWilliam Blair Brokers Increase Earnings Estimates for ZVRAMarch 15, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $25.00March 14, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Stock Price Expected to Rise, Guggenheim Analyst SaysMarch 14, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Receives Buy Rating from HC WainwrightMarch 14, 2025 | marketbeat.comEquities Analysts Offer Predictions for ZVRA FY2029 EarningsMarch 14, 2025 | marketbeat.comZevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 14, 2025 | finance.yahoo.comZevra Therapeutics (NASDAQ:ZVRA) Receives Overweight Rating from Cantor FitzgeraldMarch 13, 2025 | marketbeat.comZevra Therapeutics’ Earnings Call Highlights Success and GrowthMarch 12, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHST, ERAS, ZVRA, and ALT Company DescriptionsAltimmune NASDAQ:ALT$4.78 +0.04 (+0.84%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$4.60 -0.19 (-3.87%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.BioHarvest Sciences NASDAQ:BHST$6.15 -0.34 (-5.24%) As of 04/2/2025 03:43 PM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Erasca NASDAQ:ERAS$1.26 +0.06 (+4.56%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$1.22 -0.04 (-3.57%) As of 04/2/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Zevra Therapeutics NASDAQ:ZVRA$7.66 +0.34 (+4.64%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$7.45 -0.21 (-2.73%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Boeing Stock Upgraded After Beating Lockheed for Jet Deal Amazon Falls Back to a Key Support Line: Here's How to Play It Why Howmet Could Be the Sleeper Aerospace Name of 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
